INmune Bio, Inc. (INMB)
NASDAQ: INMB · Real-Time Price · USD
2.000
+0.030 (1.52%)
Sep 16, 2025, 12:30 PM EDT - Market open
INmune Bio Employees
As of December 31, 2024, INmune Bio had 22 total employees, including 13 full-time and 9 part-time employees. The number of employees increased by 5 or 29.41% compared to the previous year.
Employees
22
Change (1Y)
5
Growth (1Y)
29.41%
Revenue / Employee
$2,273
Profits / Employee
-$2,523,091
Market Cap
53.17M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 22 | 5 | 29.41% |
| Dec 31, 2023 | 17 | 7 | 70.00% |
| Dec 31, 2022 | 10 | 0 | - |
| Dec 31, 2021 | 10 | 5 | 100.00% |
| Dec 31, 2020 | 5 | 1 | 25.00% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
INMB News
- 5 weeks ago - INmune Bio, Inc. (INMB) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 6 weeks ago - INmune Bio's CaRe PC Trial of INKmune™ in Metastatic Castration-Resistant Prostate Cancer Meets Endpoints and Is Closed to Enrollment - GlobeNewsWire
- 6 weeks ago - INmune Bio Inc. to Report Second Quarter 2025 Financial Results and Provide Corporate Update on Thursday, August 7th - GlobeNewsWire
- 7 weeks ago - INmune Bio to Publish Video Detailing MINDFuL Trial Findings of XPro™ Presented at the Alzheimer's Association International Conference - GlobeNewsWire
- 2 months ago - INmune Bio: Thinking Through XPro's MINDFuL Data In Early Alzheimer's - Seeking Alpha
- 2 months ago - 'Pharma Bro' Martin Shkreli Says 'Good Chance' Inmune Bio Stock Will Slip 90% On Monday - Benzinga
- 2 months ago - INmune Bio, Inc. Announces Closing of Approximately $19 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules - GlobeNewsWire
- 2 months ago - Alzheimer's Setback Hits INmune Bio Stock, But FDA Hopes Remain - Benzinga